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Summary: We describe an improved procedure using a standard microplate immunoassay reader to measure the
concentration of troponin T in human serum. We also describe an immunoassay for troponin I in serum. Only 160 μΐ
of serum are needed for a single analysis of each troponin. For comparison, creatine kinase MB mass analysis in
serum was performed with a commercial luminometric method. From 95 apparently healthy people the following
values were obtained: creatine kinase MB mass 2.6 ±1.2 μg/l, troponin Τ 0.027 ± 0.025 μg/l and troponin I
0.03 ± 0.031
We compared the results of troponin Τ and troponin I methods with each other, as well as with those of creatine
kinase MB mass measured in 48 patients with verified acute myocardial infarction and in 60 control patients with
non-cardiac chest pain. The correlation between troponin Τ and troponin I values was 0.91 for the total material and
0.94 for 48 patients with acute myocardial infarction. Troponin I showed better earlier sensitivity than troponin Τ
(ρ = 0.043). In nine patients in the control group, creatine kinase MB mass exceeded the reference limit of 5.0 μg/l,
while in two patients the cut-off limit of 10.0 μ§/1 was also surpassed, pointing to non-specificity.
In the group of infarct patients, the highest serum creatinine value was 193 μηιοΐ/ΐ, whereas in the control group it
was 406 μιηοΙ/1. The sera of patients with impaired renal function without any cardiac failure showed no increase
in troponin Τ and troponin I values.
In conclusion, serum creatine kinase MB mass and troponin I seem to confirm an acute myocardial infarction more
rapidly than does troponin T; troponin I has the highest cardiac specificity.
Introduction
Troponin T, troponin I and troponin C belong to the Troponin Τ and troponin I are proteins found in both
family of troponins in muscle tissues (1, 2). Troponins myocardial and in skeletal muscles. Analysis of the
are located in the thin filament of the myocyte. Troponin amino acid contents and the structure of troponin T
T has the highest relative molecular mass (Mr = 37000), and troponin I (7, 8) has verified that there are such
while the relative molecular mass of troponin I is Mr marked structural differences between myocardial and
= 24000 and that of troponin C is Mr = 20000 (2). The skeletal proteins in adults that distinct and highly spe-
function of troponin T is to bind the other troponins to the cific antibodies against myocardial troponin T and tro-
tropomyosin filament of the myocyte, while troponin I in- ponin I can be produced (4, 5, 7—9). Using two
hibits actomyosin ATPase, and troponin C binds Ca2+ selected monoclonal antibodies, Katus and coworkers
ions (3). When cardiac muscle fibres are damaged they re- (10) developed a new, highly specific enzyme-linked
lease first the cytosolic and subsequently the complexed immunosorbent assay (ELISA) method for the mea-
troponins into the circulation (4,5). In cardiac muscle this surement of serum cardiac troponin T, and showed
release depends on the recanalization of the damaged that skeletal troponin T has minimal crossreactivity
muscle area, which is much more advanced in cases of with this antibody. Likewise, Lame and coworkers (5)
early reperfusion than in a stabile occlusion (4, 5). This developed an immunoenzymometric assay using two
provides a means of following the progress of the myocar- very specific antibodies for measuring troponin I in
dial infarction as a function of time (4-6). human serum. Many recent studies have shown that
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the troponin T and troponin I methods are very useful
in the diagnosis of acute myocardial infarction and
for estimating the fate of the patients with unstable
angina pectoris (3, 5, 6, 10—13).
In this article we describe an improved modification of
our ELISA procedure (14) for measuring troponin T
using a standard microtitre plate immunoassay reader
(15) and an ELISA procedure for troponin I. For com-
parison, creatine kinase MB1) mass was measured in se-
rum.
The main purpose of the present investigation was to
study the usefulness of the immunochemical methods
for troponin T and I, as well as for creatine kinase MB
mass, to distinguish patients with definite acute myocar-
dial infarction from those with non-cardiac chest pain.
This formed part of a larger study of patients coming to
the hospital with chest pain. For this purpose we tried to
reduce the between-series variation of our troponin T
procedure (14). Secondly we studied the use of tro-
ponin I in the diagnosis of acute myocardial infarction
using a standard microtitre immunoassay technique.
And thirdly we compared the usefulness of serum
troponin T, troponin I and serum creatine kinase MB
mass values in serum for monitoring patients after
onset of chest pain.
Materials and Methods
Samples
For the present study, part of the samples from patients of the emer-
gency department of the Kuopio University Hospital were taken
for ordinary serum enzyme assays (creatine kinase, creatine kinase
isoenzyme MB and lactate dehydrogenase isoenzyme I)1) and
stored at -70 °C until analysed for troponin T, troponin I and cre-
atine kinase MB mass. Venous blood samples for enzyme deter-
minations were collected with minimal stasis and centrifuged
within 60 min to obtain serum for analyses. Haemolysed samples
were replaced by new samples. For measuring the variations
within-series and between-series, two serum pools were made, di-
vided into 1.0 ml portions and stored at —70 °C until analysed.
Forty-eight consecutive patients with acute myocardial infarction
(16) and 60 patients with non-cardiac chest pain were enrolled at
the emergency care department for the study. The patients were
classified into diagnostic categories using modified FINMONICA
criteria, which are based on symptoms, electrocardiographic find-
ings and traditional enzymes. The clinical data of the patients is
presented in detail in table 1.
In addition, the creatine kinase MB mass, troponin T and troponin
I values were measured in the sera of 95 apparently healthy people
(students, laboratory personnel and firemen, assessing as healthy
by determination of blood haemoglobin and packed cell volume
and differential blood cell count).
Methods and reagents
Serum troponin T was previously measured by using the Troponin-
T kit of Boehringer Mannheim (Mannheim, Germany) for the ES-
series of analysers. For the determination of troponin T as a micro-
titre plate immunoassay method, unmodified reagents for the Enzy-
mun-Test® (Cat. No. 1556428) produced by Boehringer Mannheim
were used (14). Instead of the original tubes, the reaction was per-
formed in the 250 μΐ wells of a microtitre plate after coating the
wells with streptavidine. Commercial microtitre plates coated with
streptavidine (Labsystems Co., Helsinki, Finland) were found to be
useful. Coated microtitre plates were stored at + 4 °C until used.
Otherwise, the method was performed in a similar way to that pre-
sented earlier (14) with minor modifications (15). Standard, control
and serum (30 μΐ each) were dispensed into the wells of the plate
with a manual Proline 5—50 pipette of Biohit Co. (Helsinki, Fin-
land). The tip of the pipette was changed after each operation. A
mixture of antibodies to troponin T (200 μΐ) was then added with
a multitip automated pipette (Proline Electronic 250, Biohit Co.),
and the plate was incubated for 30 min at 25 °C in a shaker (Well-
warm 1 Shaker, Denley, England) and washed twice with the wash-
ing solution using a Multiwash instrument (Labsystems Co.). Then
the substrates (di-ammonium 2,2'-azino-bis[3-ethylbenzothiazol-
ine-6-sulphonate] and H2O2) were added and the microtitre plate
was incubated on a Multiscan MCC/340 reader (Labsystems Co.)
for 10 min, after which the intensity of the colour in the wells was
read at 405 nm. The concentrations of troponin T were then ob-
tained from a standard curve prepared by the Genesis® program of
Labsystems Co. using a microcomputer connected on-line to the
Multiscan reader.
The standard curve for troponin T was constructed as follows:
Standards were 0.0, 0.9, 2.4, 5.2, 10.7 and 14.5 μ§/1. The concen-
trations in the controls purchased with the kit were low (0.19
± 0.06 μg/l) and high (5.45 ± 0.82 μg/l).
The concentration of troponin I in serum (troponin I) was measured
using the reagents from the Spectral Co. (Toronto, Canada) as re-
commended by the manufacturer as follows: Microtitre plates of
Biohit Co. (12 PCS 8-well strips/plate) were coated with goat anti-
troponin I antibody at 4.0 mg/1 in 0.1 mg/1 sodium citrate buffer,
pH 4.0 overnight. After washing the wells four times with 0.1 mol/1
phosphate buffer, pH 6.8 containing 0.15 mol/1 of NaCl, the wells
were incubated with 250 μΐ of blocking buffer (digested casein, 10
g/1 in 0.3 mol/1 NaCl) for 60 min, washed four times with 0.1 mol/1
phosphate/0.15 mol/1 NaCl buffer, pH 7.0 containing 250 μΐ/ΐ of
Tween-20, and once with 0.1 mol/1 phosphate/0.15 mol/1 NaCl
buffer and then dried. Standard, control or serum were added to
the appropriate well in duplicate. Then 50 μΐ of incubation buffer
(50 μΐ each) containing detector antibodies (monoclonal antibodies
Mab 81-7 and Mab 21-14 at 5 mg/1 in EDTA-Tris-casein, NaCl and
Tween-20 buffer, pH 6.0) were added to each well and the plate
incubated at 25 °C for 45 min on a shaker (200 min~!). After wash-
ing four times with phosphate/NaCl buffer with Tween-20 and once
with phosphate/NaCl buffer as before, the wells were dried. Instead
of the o-phenylenediamine dihydrochloride substrate used by
Tab. 1 The basic clinical data of the patients participating in the
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Creatine kinase (EC 2.7.3.2)
Creatine kinase isoenzyme MB
Lactate dehydrogenase (1.1.1.27) isoenzyme 1
chest pain to hospitalization, h
Number of deaths during
hospitalization
Number of patients with
thrombolytic treatment
24
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Tab. 2 The schemes for the determination of serum troponin T substrate di-ammonium 2,2'-azino-bis(3-ethylbenzothiazoline-6-
and troponin I using the microplate immunoassays. ABTS® = sulphonate).
Action
Coating of the microtitre plate wells
Sample/Standard
Anti-troponin T antibody, biotinylated and anti-troponin T antibody, enzyme conjugated
Anti-troponin I, enzyme conjugated
1
The microtitre plates were incubated at 25 °C for
Washings of the wells with washing solutions
Addition of reagents ABTS® and H2O2
I


















Measurement of the colour directly from the microtitre plate wells at 405 nm.
Results obtained from the standard curves made by the Genesis® program
Spectral Co., 120 μΐ of the substrates (di-ammonium 2,2'-azino-
bis[3-ethylbenzothiazoline-6-sulphonate, Sigma Co.] and H2O2)
were added and the microtitre plate was incubated on a Multiscan
MCC/340 reader (Labsystems Co.) for 10 min at room temperature
in the dark, after which the intensity of the colour in the wells was
read at 405 nm. The concentrations of troponin I were then ob-
tained from a standard curve prepared by the Genesis® program of
Labsystems Co. using a microcomputer connected on-line to the
Multiscan reader.
The standard curve for troponin 1 was constructed by using the
following standards from the manufacturer: 0.0, 0.1, 0.2, 0.39,
0.78, 1.56, 3.125, 6.25, 12.5 and 25 μ§/1. The controls purchased
from the manufacturer were low (0.39 ± 0.09 μg/l) and high (7.45
± 0.92
Serum creatine kinase (EC 2.7.3.2) was measured with a commer-
cial assay from Boehringer Mannheim according to the ECCLS
recommendation (17), using a Hitachi 717 analyser (Tokyo, Ja-
pan). The activity of the creatine kinase B isoenzyme was mea-
sured after inhibiting the M-subunit with anti-creatine kinase Μ
antibody (Boehringer Mannheim), and expressed as the value of
creatine kinase MB by doubling the measured creatine kinase Β
value. The activity of lactate dehydrogenase (EC 1.1.1.27) and
its isoenzyme 1 after inhibition of the M-containing isoenzymes
with urea and guanidine at pH 10 was measured according to
the lactate dehydrogenase method of Boehringer Mannheim using
a Hitachi 717 analyser in accordance with the Scandinavian
Recommendation (18).
The mass concentration of creatine kinase MB in serum was mea-
sured using a monoclonal anti-creatine kinase MB antibody bound
to latex microparticles and a second polyclonal anti-creatine ki-
nase-MM antibody coupled with alkaline phosphatase (19) by a
commercial IMx® creatine kinase MB assay (Abbott Laboratories,
Abbott Park, 111., USA).
The creatinine concentration in serum was measured with an auto-
mated kinetic alkaline picrate method using a Hitachi 717 Analyser.
The reference values of serum creatinine for men are 60—105 and
for women 50—90 umol/l.
Statistics
Student's t-test and a non-parametric test (Wilcoxon's signed rank
test) were used to compare results between methods and patient
groups using the StatView 4.0 software package (Abacus Concepts
Inc., Berkeley, Ca., USA). The correlations between the method
groups were performed using a two-by-two contingency tables test
with SPSS/PC + software package version 5.0.1 (20).
Results
The patients with chest pain were classified into diagno-
sis categories using FINMONICA criteria based on the
recommendation of WHO (16). All 48 patients with
acute myocardial infarction had typical symptoms, diag-
nostic electrocardiographic findings and elevated cre-
atine kinase, creatine kinase isoenzyme MB and lactate
dehydrogenase 1 activity values in serum. In contrast,
the control group consisted of 60 patients, who had no
infarction, no abnormal electrocardiographic findings
and ordinary enzyme activity values; although they had
chest pain this was apparently not of cardiac origin. The
creatine kinase MB mass, troponin T and troponin I val-
ues in the serum of these patients were then measured
to evaluate the usefulness of creatine kinase MB mass
and troponins in the diagnosis of acute myocardial in-
farction.
Evaluation of the microtitre plate ELISA
methods for the determination of troponin T
and troponin I
Initially, the linearity of the Multiscan microtitre plate
reader to be used in the measurements was studied. By
using different dilutions of potassium dichromate, the
instrument was found to be linear at 405 nm up to
A405 = 2.400 using different dilutions of dichromate. At
absorbances of 0.3 and 1.5, the readings from the 250
μΐ wells containing 200 μΐ of the colour red solution
revealed variations below 1.0%.
Using increasing concentrations of troponin T, it was
found that the streptavidine coating of every 250 μΐ well
should be able to bind at least 2 ng of biotin for proper
functioning of the assay. The incubation times and tem-
perature were also studied, and it was shown that assays
can be performed at 25 °C and that 30 min for the antigen-
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antibody reaction and 10 min for the colour reaction were
optimal. The microtitre plate must be washed mechani-
cally, not manually, in order to obtain consistent results.
The microtitre plates for troponin I measurement were
coated with the first monoclonal antibody against tro-
ponin I and the wells treated with digested casein to
prevent unspecific binding of troponin I. The corre-
sponding incubation times for the troponin I measure-
ment were 45 min and 10 min.
The highest standard of troponin T was 14.5 μ§/1, and
that of troponin I was 25 μg/l. In the daily laboratory
practice a few troponin Τ values are higher, requiring
dilution of the samples; this is often necessary for the
measurement of troponin I. The only obvious problem
in the standardization of troponin T was that there is
no standard near the critical value of the measurement
(between 0.1-0.2 μg/l). This kind of standard would
assist greatly in the accurate measurement of low tro-
ponin Τ values. The reagents for troponin I supplied to
us also contained standards at the critical measurement
levels of 0.1—0.2 μg/l. However, the standard curve of
troponin I was not as steep as that of troponin T.
The variations within-series and between-series were
studied using control samples and frozen serum pools.
The within-series variations of the methods were accept-
able for creatine kinase MB mass, troponin Τ and tro-
ponin I (tab. 3), being below 10%. The variations be-
tween-series were higher and ranged from 4.7 to 8.7%
for creatine kinase MB mass and troponin Τ (tab. 3).
The between series variation of troponin T was smaller
than in the first modification (14), after addition of a
microcomputer with the Genesis® program for the cal-
culation of the results. The between series variation of
troponin I was below 10.4% (tab. 3).
In sera of healthy control persons (n = 95) there was
very little if any troponin Τ and troponin I, while cre-
atine kinase MB mass showed measurable values (2.6
± 1.2 μg/l). In sera of healthy persons the mean value
of troponin T was 0.027 ± 0.025 μ^, the highest value
being 0.19 μg/l. More than 95% of all troponin Τ values
from healthy persons were below 0.1 μg/l. By doubling
this value, it can be stated that troponin Τ values in
serum greater than 0.2 μg/l should be regarded as abnor-
mal. In comparison, the reference values for troponin I
were 0.03 ± 0.031 μg/l, all values were below 0.1 μg/l
and the cut-off limit of 0.2 μg/l was used. For creatine
kinase MB mass, the upper normal limit was 5.0 μg/l
and a cut-off limit of 10 μg/l was selected.
Comparison of the methods in the diagnosis
of patients with acute myocardial infarction
The suitability of the measurements of serum troponin
Τ and troponin I by microtitre plate ELISA procedures
for the diagnosis of acute myocardial infarction was
tested using serum samples from 48 patients with veri-
fied acute myocardial infarction. The results in figures
la, b and c show that during the episode, the creatine
kinase MB mass, troponin Τ and troponin I were ele-
vated above the cut-off limits after the onset of the chest
pain in all patients with acute myocardial infarction.
Troponin Τ stayed elevated longer than troponin I. The
correlation between serum troponin Τ and troponin I
values was very high (0.91) in the total material and
even higher in the infarct group alone (0.94).
In the control group none of the patients showed any
increase in troponin I values in serum (fig. 2c) and only
one troponin Τ value was more than the cut-off limit of
0.2 μg/l (fig. 2b). During the hospitalization period nine
control patients showed serum creatine kinase MB mass
values between the upper reference limit and the cut-off
limit, and two control patients showed values actually
over the cut-off limit (fig. 2a), while their troponin Τ and
troponin I values were completely normal with normal
electrocardiographic findings.
In figure 3, the behaviour of creatine kinase MB mass,
troponin Τ and troponin I is seen in the sera of 42 pa-
tients arriving at the hospital within 12 hours after onset
of chest pain. On admission to the hospital it was found
Tab. 3 The within-series and between-series variation of creatine
kinase MB mass, troponin Τ and troponin I methods using low and
high serum pools.
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that 29 patients had elevated creatine kinase MB mass
value in serum, 22 had an elevated troponin T value and
28 an elevated troponin I value. The cumulative increase
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rate as that of troponin I (p = 0.109), while
of troponin Τ was significantly slower (p =
the increase
0.043) than
that of creatine kinase MB mass (fig. 3). The difference
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Time after onset of chest pain [h] Time after onset of symptoms [h]
Fig. 1 Typical behaviour of serum creatine kinase MB mass val- Fig. 2 The behaviour of creatine kinase MB mass (a), troponin T
ues (a), troponin T values (b) and troponin I values (c) after onset (b) and troponin I (c) values in sera of 60 patients in the control
of chest pain in 48 patients with acute myocardial infarction. group.
The lines with the arrow designate the cut-off limits. The lines with the arrow designate the cut-off limits.
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Time after onset of chest pain [h]
Fig. 3 The changes of creatine kinase MB mass (-Π-), troponin
T (-·-) and troponin I (-·-) values in 42 sera from infarct patients
arriving at the hospital within 12 h after the onset of chest pain.
The values are expressed as per cent of the patients whose values
exceeded the corresponding cut-off limits of 10 μ§/1 and 0.2 μg/l
at different times after onset of chest pain. The significances of the
differences between the areas under the curves were: significant
between creatine kinase MB mass and troponin Τ (p = 0.043) and
troponin Τ and troponin I (p = 0.043) but insignificant between
creatine kinase MB mass and troponin I (p = 0.109).
also significant (p = 0.043). At 12 h after admission, all
patients with acute myocardial infarction showed cre-
atine kinase MB mass and troponin I values over the
corresponding cut-off limits, while troponin T was be-
low 0.2 μg/l in two patients at 12 h and in one patient
at 24 h, subsequently exceeding the cut-off limit of 0.2
μg/l. At admission and during the hospitalization period,
all patients in the control group had troponin I values
below 0.2 μg/l and one troponin T value was just over
the cut-off limit (0.24 μg/l), whereas at admission five
patients had creatine kinase MB mass values between
5.0 and 10.0 μg/l and two patients had values over the
cut-off limit of 10.0 μ^Ι. However, the extent of the
increase (value at six hours/value at admission) was
highest in the case of troponin Τ (quotient 58), being
somewhat smaller for troponin I (quotient 32), and
smallest for creatine kinase MB mass (quotient 20).
The effect of renal failure was studied by measuring creat-
inine and troponin values from sera of patients in the con-
trol group. The results showed that the troponin Τ and tro-
ponin I values were below the cut-off limit of 0.2 μg/l in
sera of all control patients whose creatinine values were
over the reference limits and showed concentrations up to
406 μιηοΐ/l. On the other hand, the highest creatinine
value in the group of infarct patients was only 193 μηιοΐ/ΐ.
Discussion
Comparison of the values obtained with the microtitre
plate immunoassay methods for serum troponin Τ and
troponin I showed very similar results for diagnosing
acute myocardial infarction in patients with acute chest
pain. The variation of the methods within-run and be-
tween-run were acceptably small for both analyses and
correspond quite well to those presented for troponin Τ
by Heiland et al. (21) and for troponin I by Kuhr et al.
(22). The troponin T stayed elevated longer than tro-
ponin I, returning to a normal level within two weeks,
while troponin I remained elevated for about nine days
with a peak at 24 h. The release kinetics of troponin I
were similar to those of troponin T, showing both mono-
phasic and biphasic responses depending on reperfusion
(6), but troponin T showed the biphasic response more
often than did troponin I.
The troponin I values in sera of the normal population
(n = 95) were below 0.1 μg/l (below the detection limit,
defined as the mean of 10 non-specific binding measure-
ments + 3 SD), and more than 95% of troponin T values
were lower than 0.1 μg/l. Both troponin T and troponin
I were not increased in sera of control patients with renal
failure whose serum creatinine showed a maximum
value of 406 μτηοΐ/ΐ. This finding differs from that of
Bhayana et al. (23) for troponin T but is in accordance
with their results for troponin I. From a practical point
of view, it seems quite evident that the present methods
meet the needs of routine clinical laboratory practice in
the diagnosis of acute myocardial infarction, since these
proteins were not detected in the serum of patients with
non-cardiac diseases (5, 22, 24).
Katus et al. (10) showed that the lower detection limit
for measurement of troponin T is 0.04 μ^Ι and Gerhardt
et al. (25) reported that the upper limit for healthy blood
donors for troponin T in serum is 0.06 μ§/1. Bodor et al.
(11), Kuhr et al. (22), Bertinchant et al. (26) and Mair
et al. (27) did not find troponin I in sera of patients
without cardiac disease (not detectable). These reports
correspond well with the present findings of troponin T
and troponin I in the sera of healthy people and patients
not suffering from cardiac disease.
Lindahl et al. (28) reported that the determination of
troponin T is a widely applicable method for diagnosing
patients acute myocardial infarction, together with myo-
globin or creatine kinase MB mass. Adams et al. (29)
reported that cardiac troponin I is a sensitive and spe-
cific method for the diagnosis of perioperative myocar-
dial infarction and Antman et al. (13) predicted that tro-
ponin I is a good marker of acute myocardial damage.
The present findings from the infarct and control groups
are in agreement, indicating that the specificity of both
troponin T and troponin I is very high and that the pa-
tients with acute myocardial infarction are well diag-
nosed.
When the behaviour of the cardiac markers creatine ki-
nase MB mass, troponin T and troponin I were com-
Penttilä et al.: Troponin T and I in diagnosis of acute myocardial infarction 773
pared with each other, it was found that creatine kinase
MB mass and troponin I increased more rapidly in se-
rum of patients with acute myocardial infarction than
did troponin T. However, in clinical use there were no
major differences between creatine kinase MB mass and
troponins in terms of sensitivity and specificity; only the
time windows were different. According to the present
results, at six hours after admission to the hospital, 95%
of creatine kinase MB mass, 88% of troponin T and
93% of troponin I values were elevated in the infarction
group; at 12 hours all creatine kinase MB mass and tro-
ponin I values were elevated, while troponin T was ele-
vated at 12 h in 95%, at 24 h in 98% and at 36 h in
100% of patients with myocardial infarction. Thus it
seems that creatine kinase MB mass and troponin I val-
ues become positive slightly earlier than troponin T (fig.
3) after onset of acute myocardial infarction, in agree-
ment with the findings of Mair et al. (30). It is quite
evident that troponin I in the sera of patients with a
myocardial infarction is increased somewhat earlier than
troponin T (fig. 3). It may be that the smaller molecular
mass of troponin I compared with that of troponin T
accounts for this difference (2). However, the extent of
the increase of troponin T in serum from the initial value
was more pronounced for troponin T than for troponin I
and creatine kinase MB mass.
Recently, Müller-Bardoff el al. (31) published details of
a second generation test for the measurement of troponin
T in serum. With this new method most problems asso-
ciated with the first generation troponin T method have
now been eliminated. But the studies of Bodor et al.
(32) on cardiac troponin T composition in normal and
regenerating human skeletal muscle showed that the
cardiac troponin T isoform is expressed in certain mus-
cular diseases in adults, and that this is not observed for
troponin I (33, 34). The very recent findings of Davies
et al. (34), for the measurement of troponin I using the
antibodies against troponin I from Spectral Co., con-
firmed that cross-reactivity with skeletal troponin I was
absent in concentrations up to 2.0 mg/1. This means that
troponin I methods (5, 33, 34) are very specific for
cardiac muscle damage in patients without renal failure,
while troponin T is not 100% specific for cardiac dam-
age (24, 26, 31, 32).
Conclusions
The measurement of creatine kinase MB mass and tro-
ponin I in sera of patients with acute chest pain seemed
to be efficient in revealing acute myocardial infarction,
while troponin T increased significantly more slowly
than creatine kinase MB mass and troponin I. Troponin
I, according to the present results, provides an earlier
diagnosis of myocardial infarction than troponin T. On
the other hand, creatine kinase MB mass measurements
can be performed on request 24h/day (35) in smaller
laboratories. The diagnosis of acute myocardial infarc-
tion is then confirmed by measuring either troponin T
or troponin I from samples taken at 0 and 4—6 hours
after admission to the hospital.
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